Shots :Dr. Mourad talked about the positive P-III data showing results for BIIB800, a Tocilizumab biosimilar candidate presented at the Annual European Congress of Rheumatology (EULAR 2022)He also spoke about the results of the 48-week analysis of the PROPER trial evaluating adalimumab biosimilar, Imraldi, in patients with autoimmune diseasesThe interview highlights Biogen's…
